|
Activity Number:
|
355
- Contributed Poster Presentations: Biopharmaceutical Section
|
|
Type:
|
Contributed
|
|
Date/Time:
|
Tuesday, July 30, 2019 : 10:30 AM to 12:20 PM
|
|
Sponsor:
|
Biopharmaceutical Section
|
|
Abstract #305309
|
|
|
Title:
|
A Comparison of Migraine Prevention Therapies in the Adult Versus Pediatric Populations Using a Joint Bayesian Network Meta-Analysis Model
|
|
Author(s):
|
Zachary Thomas* and Phebe Kemmer and Tianle Hu and Fanni Natanegara and Himanshu Upadhyaya
|
|
Companies:
|
Eli Lilly and Company and Eli Lilly and Company and Eli Lilly and Company and Eli Lilly and Company and Eli Lilly and Company
|
|
Keywords:
|
Network meta-analysis;
Bayesian;
Migraine;
Clinical trials
|
|
Abstract:
|
The prevalence of migraine in children and adolescents is 7.7%. Although 8 medications are currently FDA-approved for migraine prevention in adults, only 1 (topiramate) is FDA-approved for adolescents due to the lack of positive studies. Many pediatric studies in migraine are small and potentially underpowered, although many show a numerical trend toward efficacy. Given the similarities of the disease between the two populations, it is of scientific interest to assess whether the treatment effect in adults could be reliably extrapolated to pediatric patients. We perform a literature review to curate data from randomized placebo-controlled clinical trials of migraine preventives in adult and pediatric patients. We conduct a joint Bayesian network meta-analysis that synthesizes the curated data under one framework and quantifies the similarity of the treatment effect for adult vs. pediatric patients. The analysis demonstrates a reasonable level of concordance between adult and pediatric efficacy results, yielding support for partial extrapolation in pediatric patients using results in adults. These findings can be leveraged to power future studies in pediatric migraine.
|
Authors who are presenting talks have a * after their name.
